If you're currently receiving compounded GLP-1 medication from a telehealth platform, there's a two-character distinction that will determine whether your supply chain survives the next 18 months: 503A versus 503B. Most consumers have never heard these terms. By the end of 2026, they may be the most important letters in your treatment plan.
The core issue is simple: the regulatory framework that enabled mass-market compounded GLP-1s through telehealth was built on a temporary exception during drug shortages. That exception is closing. What remains legal is narrower than most patients — and many platforms — seem to realize.
The Regulatory Framework, Simplified
503A compounding pharmacies prepare medications one patient at a time, based on individual prescriptions from a licensed prescriber who has determined a clinical need for a compounded formulation. These pharmacies are primarily regulated by state pharmacy boards. They can legally compound semaglutide for a specific patient with a valid prescription and documented clinical need — even outside of a shortage context.
503B outsourcing facilities are registered with the FDA and can produce compounded medications in larger batches without patient-specific prescriptions. This is the model that enabled telehealth platforms to offer compounded GLP-1s at scale: the outsourcing facility produces large quantities, maintains inventory, and ships to patients as prescriptions are generated.
The critical difference: 503A requires a patient-specific prescription with documented clinical need before the medication is compounded. 503B allows anticipatory compounding — making the medication in advance and matching it to patients later. It's the difference between a tailor making a custom suit and a factory producing sizes for a warehouse.
Why 503B Is Under Threat
During the semaglutide and tirzepatide shortages (roughly 2022-2024), 503B outsourcing facilities had a clear legal basis to compound these drugs at scale. The Federal Food, Drug, and Cosmetic Act permits outsourcing facilities to compound drugs that are on the FDA shortage list.
That shortage basis is gone. The FDA lifted the shortage designation for semaglutide in October 2024 and tirzepatide later that year. Since then, the regulatory rationale for 503B mass compounding has been eroding step by step. The April 2026 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List would close the remaining pathway for outsourcing facilities.
What "Documented Clinical Need" Actually Means
Under 503A, a prescriber can order compounded semaglutide when there's a documented clinical justification for why the commercially available product doesn't meet the patient's needs. Legitimate clinical needs include:
- Allergy or sensitivity to an inactive ingredient in the branded product
- Need for a concentration or delivery method not commercially available
- Medical necessity for a preservative-free formulation
- Legitimate dosing requirements not available in commercial presentations
What does not constitute clinical need: lower cost, patient preference for compounded over branded, or the prescriber's general belief that compounded products are equivalent. State pharmacy boards are increasingly scrutinizing these determinations, and prescribers who rubber-stamp clinical need without genuine medical justification face disciplinary action.
What This Means for Telehealth Platforms
The business model of most GLP-1 telehealth platforms depends on 503B outsourcing facility partnerships. If 503B access ends, these platforms face a binary choice: pivot to branded medication distribution (as Hims did) or attempt to operate under 503A limitations — which cannot support the volume, speed, or pricing that made their business models work.
Platforms that have already established branded distribution partnerships (with Novo Nordisk for Wegovy, Eli Lilly for Zepbound) are better positioned to survive the transition. Platforms that remain entirely dependent on compounded supply chains face existential risk.